Objective: This study reports the percentage of breast cancer survivors receiving ongoing benzodiazepines and the circumstances surrounding their usage. Methods: The medical records of 1,000 consecutive breast cancer survivors who were no longer receiving adjuvant chemotherapy were reviewed. Results: Among those patients, 7.9% (95% confidence interval 6.2–9.6; higher than the 3% rate in the general population) were receiving benzodiazepines. Lorazepam was most commonly prescribed. Sixty-eight patients were cancer free at their last visit, and 51 had not been taking benzodiazepines prior to their cancer diagnosis. Anxiety was the single most frequent reason for initiating and continuing benzodiazepines. Conclusion: Anxiety appears to be a common explanation for relatively high rates of benzodiazepine use in breast cancer survivors. This finding merits further study.

Keywords:
Anxiety, Cancer survivors, Benzodiazepine, Breast cancer
1.
Coben JH, Davis SM, Furbee PM, et al: Hospitalizations for poisoning by prescription opioids, sedatives, and tranquilizers. Am J Prev Med 2010;38:517–524.
2.
Cloos J-M, Ferreira V: Current use of benzodiazepines in anxiety disorders. Curr Opin Psychiatry 2008;22:90–95.
3.
Esposito E, Barbui C, Patten SB: Patterns of benzodiazepine use in a Canadian population. Epidemiol Psychiatr Soc 2009;18:248–254.
4.
Mosher CE, Duhamel KN: An examination of distress, sleep, and fatigue in metastatic breast cancer patients. Psychooncology 2010, Epub ahead of print.
5.
Kris MG, Hesketh PJ, Somerfield MR, et al: American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006;24:2932–2947.
6.
Lagnaoui R, Depont F, Fourrier A, et al: Patterns and correlates of benzodiazepine use in the French general population. Eur J Clin Pharmacol 2004;60:523–529.
7.
Fang S-Y, Chen C-Y, Chang I-S, et al: Predictors of the incidence and discontinuation of long-term use of benzodiazepines: a population-based study. Drug Alcohol Depend 2009;104:140–146.
8.
Centers for Disease Control and Prevention: Emergency department visits involving nonmedical use of selected prescription drugs. United States 2004–2008. MMWR Morb Moral Wkly Rep 2010;59:705–709.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.